HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.